ProjectALTERNATIVE: a prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine…
Basic data
Title:
ALTERNATIVE: a prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
Duration:
21/03/2016 to 20/03/2019
Abstract / short description:
ALTERNATIVE: a prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
Keywords:
clinical trial
klinische Studie
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine